In the midst of escalating geopolitical competition with China, the United States must recognize the vital importance of protecting and strengthening its clinical trial infrastructure as a cornerstone of national security.
As the landscape of global strategic leadership evolves, the ability to drive biotech innovation and swiftly develop cutting-edge therapeutics has become a defining factor in shaping international norms and alliances. With emerging biopharma firms and innovative therapies reshaping the industry, the role of contract research organizations (CROs) as the backbone of biomedical research cannot be understated. As China rapidly expands its clinical trial capabilities, the U.S. faces the risk of falling behind in a race that extends far beyond pharmaceutical markets to influence global health diplomacy and regulatory standards.
Read more from statnews.com